Feeds:
Posts
Comments

Posts Tagged ‘zoledronic acid’

URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>

Read Full Post »

URO TODAY: Placement of zoledronic acid-releasing testicular prostheses has the potential to become the preferred clinical management tool for prostate cancer patients with bone metasthases after bilateral orchiectomy. READ MORE>

Read Full Post »

JULY 12: URO TODAY: Bone loss begins at 6 months with androgen deprivation therapy (ADT). A single infusion of zoledronic acid in patients receiving ADT reduces bone mineral loss and maintains bone mineral density (BMD) at least at 12 months during ADT. Further study is needed to determine the best dosing schedule to prevent ADT-induced bone loss in men with hormone-naive prostate carcinoma. READ MORE>

Read Full Post »